[ORIGINAL ARTICLE]

Utility of a Score for Predicting Glomerular Filtration Rate Overestimation in Patients with Cardiovascular and Renal Diseases and Their Risk Factors

Tomoyuki Ishigo¹, Toshiyuki Yano², Satoshi Katano³, Ryo Takada¹, Tomohiro Aigami¹, Keita Nakano¹, Fuki Kondo¹, Hidemichi Kouzu², Katsuhiko Ohori^{2,4}, Hiromasa Nakata¹, Masatoshi Nonoyama¹, Manabu Kitagawa¹, Tomoko Kimyo¹, Masahide Fukudo¹ and Tetsuji Miura²

Abstract:

Objective We recently reported a novel score for the detection of glomerular filtration rate (GFR) overestimation using a creatinine-based equation. We examined the utility of this score in patients with cardiovascular/renal diseases and diabetes mellitus.

Methods We enrolled 1,425 patients (65±15 years old; 37% women) who were admitted to our hospital for the management of cardiovascular and renal diseases and their risk factors. Overestimation of the GFR (OE) was defined as a creatinine-based GFR (eGFR_{cre}) ≥120% of the cystatin C-based estimated GFR. The OE score was calculated as the sum of the scores for the body weight, hemoglobin concentration, and blood urea nitrogen (BUN)/serum creatinine (Scr), totaling 1 point if the body weight was <63.0 kg in men or <42.0 kg in women, 1 point if the hemoglobin concentration was <12.4 g/dL in men or <11.0 g/dL in women, and 1 point if the BUN/Scr was >26.5.

Results The proportion of patients with OE was 14.2%. The score predicted OE with a sensitivity of 70.8% and a specificity of 99.6%, and the sensitivity was increased in patients ≥75 years old (88.3%) and decreased in diabetics (58.6%). When patients were divided into subgroups by the total score, the frequencies of OE were 8% (59/754), 14% (72/502), 38% (58/151), and 72% (13/18) in patients with scores of 0, 1, 2, and 3, respectively.

Conclusion The OE score is useful for detecting elderly cases of cardiovascular and renal diseases in which eGFR_{cre} overestimates the GFR, although its utility is limited in diabetics.

Key words: creatinine, cystatin C, glomerular filtration rate, diabetes mellitus, chronic kidney disease, renal function

(Intern Med 61: 167-175, 2022)

(DOI: 10.2169/internalmedicine.7388-21)

Introduction

The accurate assessment of the renal function is crucial for making a diagnosis of and staging chronic kidney disease (CKD), selecting pharmacological agents, determining

drug dosages and predicting the prognosis in patients with cardiovascular and renal diseases and risk factors for these diseases, such as hypertension, dyslipidemia, and diabetes mellitus (DM) (1). CKD is also frequently found in cancer patients, and chemotherapy and molecular-targeted therapy are associated with a risk of overt/subclinical kidney injury.

¹Division of Hospital Pharmacy, Sapporo Medical University Hospital, Japan, ²Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan, ³Division of Rehabilitation, Sapporo Medical University Hospital, Japan and ⁴Department of Cardiology, Hokkaido Cardiovascular Hospital, Japan

Received for publication February 22, 2021; Accepted for publication May 25, 2021

Correspondence to Dr. Toshiyuki Yano, tyano@sapmed.ac.jp

Figure 1. Inclusion of patients and the assessment of OE of the GFR. (a) Flow chart of the inclusion of study subjects. (b) Scatter plot showing discordance between eGFRcre and eGFRcys. OE of the eGFR by the eGFRcre was defined in cases with an eGFRcre $\geq 120\%$ of the eGFRcys. Patients were classified into an OE group and a non-OE group. Black dots, OE group. Gray dots, non-OE group. CRP: C-reactive protein, CKD: chronic kidney disease, AKI: acute kidney injury, GFR: glomerular filtration rate, eGFRcre: creatinine-based estimated glomerular filtration rate, eGFRcys: cystatin C-based estimated glomerular filtration rate

If the dosages of such therapy are not adjusted to within the optimal ranges for the renal function, it can lead to extremely poor outcomes, including the development and progression of CKD (2). Thus, an accurate evaluation of the renal function is important in the complicated environment of a daily clinical setting.

The glomerular filtration rate (GFR), which is the rate of clearance of a substance from blood into urine, is the most acceptable indicator of the glomerular function (3, 4). Serum creatinine (Scr), a product of creatine phosphate from muscle, and serum cystatin C, an endogenous protease inhibitor derived from all nucleated cells, are currently used for the GFR measurement, since both substances are considered good indicators of the GFR, as they are freely filtered at the glomerulus, and not reabsorbed by the renal tubule, although slight secretion of Scr by the renal tubule occurs (3, 4).

At present, the creatinine-based estimated glomerular filtration rate (eGFRcre) is the most widely used indicator for the estimation of the renal function in a daily clinical setting (3, 4). However, the eGFRcre in elderly people and lean patients is frequently higher than the cystatin C-based estimated glomerular filtration rate (eGFRcys), since the plasma appearance of creatinine is reduced in people with a reduced muscle mass (3-8). Since the measurement of cystatin C is more costly than that of Scr, it is not commonly included in routine examinations (4, 9). Therefore, a tool for identifying patients whose eGFR needs to be measured using cystatin C is likely to be useful in daily clinical practice.

A score for predicting GFR overestimation (OE) due to the use of Scr was developed in an earlier study, in which many participants with a body mass index (BMI) of ≥ 30 kg/m² and participants of various races were included (10). We recently devised our own OE score to screen for cases with

OE by the eGFRcre among heart failure (HF) patients (4). In addition to the skeletal muscle mass measured by dual-energy X-ray absorptiometry, the body weight, hemoglobin level, and ratio of blood urea nitrogen (BUN) to Scr were shown to be independent predictors of OE (4). A score for the prediction of OE, composed of the body weight, hemoglobin level, and ratio of BUN to Scr, predicted OE with a good sensitivity (97.1%) and a good specificity (98.1%) among HF patients.

The present study investigated whether or not the OE score is applicable not only for HF patients but also for patients with cardiovascular and renal diseases and the associated risk factors.

Materials and Methods

This study was conducted in strict adherence with the principles of the Declaration of Helsinki and was approved by the Clinical Investigation Ethics Committee of Sapporo Medical University Hospital.

Study subjects

This study was a single-center, retrospective, observational study. Consecutive patients who were admitted to our department for the diagnosis and management of cardiovascular and renal diseases and their risk factors from April 1, 2013, to December 31, 2015, were retrospectively enrolled (Fig. 1a). Since active inflammation, thyroid dysfunction, and steroid therapy have been shown to modulate the serum cystatin C concentration in a GFR-independent manner (4, 11-14), patients with a C-reactive protein level of >1 mg/dL, those with hyperthyroidism/hypothyroidism, and those receiving corticosteroids were excluded. Patients <20

years old, those with an eGFRcre of <15 mL/min/1.73 m² or with acute kidney injury (AKI), and those with missing data were also excluded.

According to the Kidney Disease: Improving Global Outcomes (KDIGO) definition, AKI was defined in cases with any of the following: 1) increase in Scr by ≥0.3 mg/dL within 48 hours; 2) increase in Scr ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or 3) urine volume <0.5 mL/kg/h for 6 hours (15).

Laboratory data and echocardiography

Patient's information and data for blood samples including data for Scr and cystatin C for calculation of eGFRcre and eGFRcys on the first day of admission were retrieved from the patients' medical records. eGFRcre and eGFRcys were calculated using equations developed for Japanese subjects as follows: eGFRcre (mL/min/1.73 m²) = $194 \times \text{Scr}^{-1.094} \times \text{age}^{-0.287}$ (×0.739 for women) and eGFRcys (mL/min/1.73 m²) = $104 \times \text{CysC}^{-1.019} \times 0.996^{\text{age}}$ (×0.929 for women) - 8 (16). CKD was defined as an eGFRcre of <60 mL/min/1.73 m².

Definition of eGFR OE

The discordance between eGFRcre and eGFRcys was calculated as follows: (eGFRcre/eGFRcys - 1) × 100 (%), as shown in Fig. 1. OE by the eGFRcre was defined in cases where the eGFRcre was ≥120% of the eGFRcys, as previously reported (4). Patients were classified into the OE or non-OE group.

Definition of OE score and classification by total OE score

The OE score was calculated as the summed scores for the body weight, hemoglobin concentration, and BUN/Scr, as previously reported (4): 1 point if the body weight was <63.0 kg in men or <42.0 kg in women, 1 point if the hemoglobin concentration was <12.4 g/dL in men or <11.0 g/dL in women, and 1 point if the BUN/Scr was >26.5.

Statistical analyses

Data are presented as the means ± standard deviation or medians [interquartile range (IQR): 25-75th percentile] and expressed as the frequency and percentage. Welch's test was used to compare continuous variables in two groups. Differences in categorical variables between two groups were examined by the chi-squared test. The degree of OE for each group divided by the OE score was compared by the Kruskal-Wallis test, and the Steel-Dwass test was used for comparisons between each of the two groups. We calculated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy to evaluate the diagnostic ability of a score for OE in the subgroups of interest, i.e., age (<75 and ≥75 years old), and complications, such as CKD, DM, and hypertension. A p value <0.05 was considered statistically significant.

The software programs JMP[®] Pro 15 (SAS Institute, Cary,

USA) and EZR version 1.41 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria), were used for the statistical analyses in this study.

Results

Of the 2,277 enrolled patients, 852 were excluded based on the exclusion criteria, so the data for 1,425 patients were used for the analyses, as shown in Fig. 1a.

Baseline clinical characteristics

As shown in Table 1, the mean age of the patients was 64.8 ± 14.9 years old, and 37% of the patients were women. The mean body weight and BMI were 63.8 ± 15.0 kg and 24.2 ± 4.5 kg/m², respectively. Hypertension, dyslipidemia, DM, HF, ischemic heart disease (IHD), and valvular heart disease (VHD) were present in 42%, 32%, 26%, 19%, 40%, and 4% of the patients, respectively. The mean values of eGFRcre and eGFRcys were 67.2 ± 24.2 mL/min/1.73 m² and 71.8 ± 27.1 mL/min/1.73 m², respectively, and 38% and 35% of the patients were diagnosed with CKD using eGFRcre and eGFRcys, respectively.

Comparisons between the OE and non-OE groups

The proportion of patients with OE was 14.2% (202/1,425) as shown in Fig. 1b and Table 1. Patients in the OE group were significantly older than those in the non-OE group (69.3 ± 14.6 vs. 63.7 ± 14.8 years old) and included a larger proportion of women (48% vs. 36%) than the non-OE group. In the OE group, the proportions of patients with DM, HF, and VHD were significantly higher than those in the non-OE group. The albumin concentration was lower in the OE group than in the non-OE group (3.8 ± 0.6 vs. 4.1 ± 0.4 g/dL), and the eGFRcre was higher (73.5 ± 33.0 vs. 66.1 ± 22.2 mL/min/1.73 m²) and the eGFRcys lower (53.0 ± 23.0 vs. 74.9 ± 26.5 mL/min/1.73 m²) in the OE group than in the non-OE group.

Validation of the OE score in patients with cardiovascular and renal diseases and associated risk factors

When patients were divided into 4 categories according to the total score, the frequencies of OE were 8% (59/754), 14% (72/502), 38% (58/151), and 72% (13/18) in patients with scores of 0, 1, 2, and 3, respectively (Fig. 2). In analyses in which all patients were included (Table 2), a score of 1 for OE had an accuracy of 58.8%, a sensitivity of 70.8%, and a specificity of 56.8% for the prediction of OE, whereas a score of 3 had an accuracy of 86.4%, a sensitivity of 6.4%, and a specificity of 99.6% for the prediction (Table 3), indicating that the score predicted OE with a sensitivity of 70.8% and a specificity of 99.6% in the study subjects. The sensitivity of the score was increased in analyses in which patients ≥75 years old were included (sensitivity,

Table 1. Baseline Characteristics.

	All (n=1,425)	OE group (n=202)	Non-OE group (n=1,223)	p value
Age, years	64.8±14.9	69.3±14.6	63.7±14.8	<0.001
≥65, n (%)	797 (55.9%)	137 (67.8%)	660 (54.0%)	<0.001
≥75, n (%)	358 (25.1%)	77 (38.1%)	281 (23.0%)	<0.001
Female, n (%)	530 (37.2%)	96 (47.5%)	434 (35.5%)	0.001
Height, cm	161.9±9.5	157.9±9.5	162.5±9.3	<0.001
Body weight, kg	63.8±15.0	58.9±15.9	64.7±14.6	<0.001
BMI, kg/m ²	24.2±4.5	23.4±5.5	24.3±4.3	0.005
Complications, n (%)				
Hypertension	592 (41.5%)	77 (38.1%)	515 (42.1%)	0.317
Dyslipidemia	453 (31.8%)	52 (25.7%)	401 (32.8%)	0.050
Diabetes mellitus	374 (26.2%)	70 (34.7%)	304 (24.9%)	0.004
HF	277 (19.4%)	60 (29.7%)	217 (17.7%)	<0.001
IHD	571 (40.1%)	72 (35.6%)	499 (40.8%)	0.188
VHD	61 (4.3%)	17 (8.4%)	44 (3.6%)	0.004
Laboratory data				
Albumin, g/dL	4.1±0.5	3.8±0.6	4.1±0.4	<0.001
Hemoglobin, g/dL	13.5±1.9	12.6±2.2	13.6±1.8	<0.001
HbA1c, %	6.3±2.1	6.4±1.6	6.3±2.1	0.493
Creatinine, mg/dL	0.9±0.4	0.9±0.5	0.9±0.4	0.028
Cystatin C, mg/L	1.1±0.5	1.4±0.6	1.1±0.4	<0.001
BUN, mg/dL	18.4±8.6	20.8±12.4	18.0±7.8	<0.001
BUN/Scr	20.8±7.4	25.7±12.2	20.0±5.9	<0.001
eGFRcre, mL/min/1.73 m ²	67.2±24.2	73.5±33.0	66.1±22.2	<0.001
eGFRcre <60 mL/min/1.73 m ² , n (%)	534 (37.5%)	68 (33.7%)	466 (38.1%)	0.240
eGFRcys, mL/min/1.73 m ²	71.8±27.1	53.0±23.0	74.9±26.5	<0.001
eGFRcys <60 mL/min/1.73 m ² , n (%)	493 (34.6%)	127 (62.9%)	366 (29.9%)	<0.001

Data are presented as means±standard deviation or number (with percentage). $p<0.05$ was considered statistically significant. BMI: body mass index, HbA1c: hemoglobin A1c, HF: heart failure, IHD: ischemic heart disease, VHD: valvular heart disease, BUN: blood urea nitrogen, BUN/Scr: ratio of blood urea nitrogen to serum creatinine, eGFRcre: creatinine-based estimated glomerular filtration rate, eGFRcys: cystatin C-based estimated glomerular filtration rate

88.3%; specificity, 98.9%), whereas it was decreased in patients <75 years old (sensitivity, 60.0%; specificity, 99.8%). The specificity was similar among the subgroups of interest, whereas the sensitivity was higher in the subgroups with HF, IHD, and CKD and was lowest in patients with DM (Table 2). As shown in Fig. 3, the difference between eGFRcys and eGFRcre became larger as the total score increased.

Characteristics of patients with OE among patients with a score of 0

Among patients with a score of 0, the group with OE included a higher percentage of women and had a higher BMI than did the group without OE, although there was no marked difference in age between the patients with and without OE (Table 3). The proportion of patients with OE who had DM was more than two-fold higher than the proportion without OE who had DM, but the proportions of patients with hypertension and dyslipidemia were similar in patients with OE and those without OE (Table 3). The plasma levels of albumin and eGFRcys were lower and those of hemoglobin A1c (HbA1c) and eGFRcre higher in patients with OE than in those without OE (Table 3).

Discussion

The main findings in the present study were as follows: 1) the score predicted the OE with a reasonable sensitivity (70.8%) and a good specificity (99.6%), 2) the sensitivity of the score for the prediction of OE was increased in analyses of patients ≥75 years old, 3) the extent of discordance between eGFRcre and eGFRcys became larger as the total score increased, and 4) the sensitivity of the score for predicting OE was low in patients with DM. These findings suggest that cystatin C measurement is necessary for the accurate assessment of the eGFR in patients with a score of 3 and should be considered in those with a score of 1 or 2.

There is no established tool for identifying patients whose eGFR needs to be measured using cystatin C. In a previous large-scale study, Peralta et al. developed a risk score for detecting patients with an occult-reduced eGFR, defined as having eGFRcys <60 and eGFRcre >60 mL/min/1.73 m², i. e. OE by the eGFRcre (10). Among 24,877 adults who had an eGFRcre of >60 mL/min/1.73 m², 13.5% had an occult-reduced eGFR. Variables that were selected by multivariable

Figure 2. Frequencies of the GFR overestimation (OE) by the eGFRcre. Frequencies of GFR OE by the eGFRcre in patients with scores of 0 (a), 1 (b), 2 (c), and 3 (d). The total score is the sum of the scores for body weight, hemoglobin concentration, and BUN/Scr: 1 point if the body weight is <63.0 kg in men or <42.0 kg in women, 1 point if the hemoglobin concentration is <12.4 g/dL in men or <11.0 g/dL in women, and 1 point if the BUN/Scr is >26.5. OE of the eGFR by the eGFRcre was defined in cases with an eGFRcre $\geq 120\%$ of the eGFRcys. GFR: glomerular filtration rate, OE: overestimation, eGFRcre: creatinine-based estimated glomerular filtration rate, BUN/Scr: ratio of blood urea nitrogen to creatinine, eGFRcys: cystatin C-based estimated glomerular filtration rate

logistic regression analyses for developing the risk score for predicting an occult-reduced eGFR were the age, race, BMI, eGFRcre, presence of DM and hypertension, history of cardiovascular disease, and smoking habit. Although the risk score reasonably predicted an occult-reduced eGFR, the results of the analyses in subjects with an eGFRcre of >60 mL/min/1.73 m² could not be extrapolated to subjects in the present study, including CKD patients (38%). Furthermore, the predictive ability of an occult-reduced eGFR varied according to the BMI and race, which is a reasonable finding, since previous studies have shown race/region-dependent variation in the skeletal muscle mass (17, 18). Taken together, these findings suggest that the risk score for predicting OE by the eGFRcre needs to be individualized according to race and BMI.

Several factors have been shown to modulate serum cystatin C levels. First, serum cystatin C levels have been shown to be positively correlated with inflammatory markers inde-

pendently of the renal function (19). Second, a previous study revealed that the serum cystatin C level was elevated and eGFRcys was reduced under conditions of both subclinical hypothyroidism and subclinical hyperthyroidism (11). Third, the results of a study by Tsushita et al. in which the effects of doses of corticosteroids on the discordance between eGFRcys and eGFRcre were examined showed that eGFRcys/eGFRcre ratio decreases as the corticosteroid dose increases, leading to the conclusion that corticosteroids increase the serum cystatin C level, although corticosteroids have the potential to decrease the serum creatinine level through a reduction in the muscle mass (13). Although patients with these factors were excluded from the analyses in the present study to use eGFRcys as a reference standard of the GFR, other possible modulators of the serum cystatin C level have been reported. An older age, male gender, greater height/weight, and current cigarette smoking habit in addition to higher C-reactive protein levels have

Table 2. Diagnostic Ability of a Risk Prediction Score for EGFR Overestimation by EGFRcre.

	Sensitivity	Specificity	PPV	NPV	Accuracy	LR+	LR-	TP	TN	FP	FN
All (n=1,425)											
1 point	0.708	0.568	0.213	0.922	0.588	1.640	0.514	143	695	528	59
2 points	0.351	0.920	0.420	0.896	0.839	4.386	0.705	71	1,125	98	131
3 points	0.064	0.996	0.722	0.866	0.864	15.742	0.939	13	1,218	5	189
<75 years (n=1,067)											
1 point	0.600	0.623	0.174	0.922	0.620	1.592	0.642	75	587	355	50
2 points	0.288	0.954	0.456	0.910	0.876	6.309	0.746	36	899	43	89
3 points	0.040	0.998	0.714	0.887	0.886	18.840	0.962	5	940	2	120
≥75 years (n=358)											
1 point	0.883	0.384	0.282	0.923	0.492	1.434	0.304	68	108	173	9
2 points	0.455	0.804	0.389	0.843	0.729	2.322	0.678	35	226	55	42
3 points	0.104	0.989	0.727	0.801	0.799	9.732	0.906	8	278	3	69
Hypertension (n=592)											
1 point	0.714	0.557	0.194	0.929	0.578	1.613	0.513	55	287	228	22
2 points	0.338	0.917	0.377	0.902	0.841	4.044	0.723	26	472	43	51
3 points	0.052	0.996	0.667	0.875	0.873	13.377	0.952	4	513	2	73
Dyslipidemia (n=453)											
1 point	0.615	0.613	0.171	0.925	0.614	1.592	0.627	32	246	155	20
2 points	0.231	0.938	0.324	0.904	0.857	3.702	0.820	12	376	25	40
3 points	0.019	0.998	0.500	0.887	0.885	7.712	0.983	1	400	1	51
Diabetes mellitus (n=374)											
1 point	0.586	0.530	0.223	0.847	0.540	1.245	0.782	41	161	143	29
2 points	0.286	0.911	0.426	0.847	0.794	3.217	0.784	20	277	27	50
3 points	0.029	0.993	0.500	0.816	0.813	4.343	0.978	2	302	2	68
HF (n=277)											
1 point	0.800	0.447	0.286	0.890	0.522	1.447	0.447	48	97	120	12
2 points	0.483	0.857	0.483	0.857	0.775	3.383	0.603	29	186	31	31
3 points	0.133	0.986	0.727	0.805	0.801	9.644	0.879	8	214	3	52
IHD (n=571)											
1 point	0.792	0.529	0.195	0.946	0.562	1.681	0.394	57	264	235	15
2 points	0.375	0.902	0.355	0.909	0.835	3.819	0.693	27	450	49	45
3 points	0.028	0.996	0.500	0.877	0.874	6.931	0.976	2	497	2	70
CKD (n=534)											
1 point	0.794	0.500	0.188	0.943	0.537	1.588	0.412	54	233	233	14
2 points	0.471	0.869	0.344	0.918	0.818	3.595	0.609	32	405	61	36
3 points	0.088	0.989	0.545	0.881	0.875	8.224	0.922	6	461	5	62

Body weight of <63.0 kg in males or <42.0 kg in females, hemoglobin concentration of <12.4 g/dL in males or <11.0 g/dL in females, and BUN/Scr of >26.5 count for 1 point. BUN/Scr: ratio of blood urea nitrogen to serum creatinine, PPV: positive predictive value, NPV: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood ratio, TP: true positive, TN: true negative, FP: false positive, FN: false negative, HF: heart failure, IHD: ischemic heart disease, CKD: chronic kidney disease

been shown to be independently associated with serum cystatin C levels after adjusting for creatinine clearance (20). Indeed, an earlier study showed that the serum cystatin C level increases as the BMI increases (21). In addition, a positive impact of smoking on the serum cystatin C level was confirmed in a recent study showing that the serum cystatin C level was decreased three months after smoking cessation (22). Therefore, whether or not our score accurately predicts OE by the eGFRcre needs to be confirmed using GFR measurement with exogenous filtration markers, such as inulin.

One limitation of our OE score is its lower sensitivity for predicting the OE in patients with DM. This finding is explained by the results of analyses in which the clinical char-

acteristics of patients who were classified into the OE group despite having a score of 0 were examined: among patients with a score of 0, those who had OE had a higher BMI and cystatin C level as well as a higher prevalence of DM than did the patients without OE. Thus, the serum cystatin C level might be elevated by an increase in the BMI, possibly through subclinical inflammation (10, 19-21) but not a decline in the renal function, leading to discordance between eGFRcre and eGFRcys. In addition, muscle wasting is frequently observed in patients with DM, regardless of increased fat mass, which is called sarcopenic obesity; this effect contributes to the co-existence of a reduced Scr level and increased body weight (23-25). Importantly, a reduction in hemoglobin levels and elevation in BUN levels, markers

Table 3. Baseline Characteristics of Patients with OE Score of 0.

	OE group (n=59)	Non-OE group (n=695)	p value
Age, years	62.1±16.3	60.1±14.5	0.315
≥65, n (%)	34 (57.6%)	304 (43.7%)	0.042
≥75, n (%)	9 (15.3%)	108 (15.5%)	1.000
Female, n (%)	30 (50.8%)	245 (35.3%)	0.023
Height, cm	160.2±9.3	164.5±9.3	0.001
Body weight, kg	70.8±17.2	69.5±15.1	0.540
BMI, kg/m ²	27.5±6.0	25.5±4.2	0.001
Complications, n (%)			
Hypertension	22 (37.3%)	287 (41.3%)	0.584
Dyslipidemia	20 (33.9%)	246 (35.4%)	0.888
Diabetes mellitus	29 (49.2%)	161 (23.2%)	<0.001
HF	12 (20.3%)	97 (14.0%)	0.179
IHD	15 (25.4%)	264 (38.0%)	0.067
VHD	2 (3.4%)	21 (3.0%)	0.699
Laboratory data			
Albumin, g/dL	4.0±0.4	4.2±0.4	<0.001
Hemoglobin, g/dL	14.2±1.7	14.3±1.4	0.803
HbA1c, %	7.1±1.8	6.3±2.5	0.028
Creatinine, mg/dL	0.8±0.2	0.9±0.3	<0.001
Cystatin C, mg/L	1.3±0.4	1.0±0.3	<0.001
BUN, mg/dL	15.1±5.2	16.2±5.9	0.172
BUN/Scr	20.4±3.9	18.5±4.1	0.001
eGFRcre, mL/min/1.73 m ²	79.4±29.0	68.0±20.3	<0.001
eGFRcre <60 mL/min/1.73 m ² , n (%)	14 (23.7%)	233 (33.5%)	0.148
eGFRcys, mL/min/1.73 m ²	59.5±21.5	78.4±24.1	<0.001
eGFRcys <60 mL/min/1.73 m ² , n (%)	32 (54.2%)	161 (23.2%)	<0.001

Data are presented as means±standard deviation or number (with percentage). $p<0.05$ was considered statistically significant. BMI: body mass index, HbA1c: hemoglobin A1c, HF: heart failure, IHD: ischemic heart disease, VHD: valvular heart disease, BUN: blood urea nitrogen, BUN/Scr: ratio of blood urea nitrogen to serum creatinine, eGFRcre: creatinine-based estimated glomerular filtration rate, eGFRcys: cystatin C-based estimated glomerular filtration rate

of malnutrition, are not typically found at this stage of DM if patients do not have advanced-stage diabetic nephropathy. Thus, a BMI-mediated but GFR-independent elevation in the serum cystatin C level, presence of sarcopenic obesity, and absence of malnutrition are likely the primary mechanisms underlying the lack of sensitivity of the score for predicting OE in patients with DM.

Intriguingly, the utility of the eGFR for assessing the renal function in diabetic patients is a matter of debate (25). The results of a cross-sectional study by Luis-Lima et al. showed that there was poor agreement between eGFRcre or eGFRcys and the GFR measured by the plasma clearance of iothexol (“measured GFR”), which was greater in patients with a measured GFR <60 mL/min, leading to misclassification of CKD stages in approximately 30% of the study subjects (26). Given these findings, we believe that GFR measurement using exogenous filtration markers should be considered when planning dosing of drugs with a narrow therapeutic window and high toxicity in diabetic patients.

Several additional limitations associated with the present study warrant mention. First, since this study was a retrospective observational study with a limited number of study

subjects, there might have been some selection bias in the study subjects. Second, the patients enrolled in the present study were those who had been admitted to our institute for the diagnosis and treatment of cardiovascular and renal diseases as well as their risk factors. The accuracy of a score for predicting OE of the GFR using eGFRcre needs to be confirmed in outpatients with a relatively stable condition. Finally, shrunken pore syndrome is a newly proposed clinical entity characterized by a high serum cystatin C concentration with a normal Scr concentration (27, 28), the presence of which may lead to discordance between eGFRcys and eGFRcre, since creatinine (113 Da) but not cystatin C (13.3 kDa) can pass through small-sized glomerular pores freely. However, there is currently no consensus concerning the presence or definition of shrunken pore syndrome.

In conclusion, a score for predicting OE of the GFR using eGFRcre in HF patients can be favorably applied to elderly patients with cardiovascular and renal diseases as well as their risk factors. However, its utility in diabetic patients is limited.

The authors state that they have no Conflict of Interest (COI).

Figure 3. Distributions of discordance between eGFRcre and eGFRcys in groups with different scores. (a) Overall patients, (b) patients <75 years old, and (c) patients ≥75 years old. The total score is the sum of the scores for body weight, hemoglobin concentration, and BUN/Scr: 1 point if the body weight is <63.0 kg in men or <42.0 kg in women, 1 point if the hemoglobin concentration is <12.4 g/dL in men or <11.0 g/dL in women, and 1 point if the BUN/Scr is >26.5. eGFRcre: creatinine-based estimated glomerular filtration rate, eGFRcys: cystatin C-based estimated glomerular filtration rate, BUN/Scr: ratio of blood urea nitrogen to creatinine

Financial Support

This study was supported by a grant (Ishigo T) from the Japanese Society of Nephrology and Pharmacotherapy.

Tomoyuki Ishigo and Toshiyuki Yano equally contributed to this work.

References

- Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation* **139**: e840-e878, 2019.
- Torres da Costa E, Silva V, Costalonga EC, et al. Assessment of kidney function in patients with cancer. *Adv Chronic Kidney Dis* **25**: 49-56, 2018.
- Porrini E, Ruggerenti P, Luis-Lima S, et al. Estimated GFR: time for a critical appraisal. *Nat Rev Nephrol* **15**: 177-190, 2019.
- Ishigo T, Katano S, Yano T, et al. Overestimation of glomerular filtration rate by creatinine-based equation in heart failure patients is predicted by a novel scoring system. *Geriatr Gerontol Int* **20**: 752-758, 2020.
- Abe K, Yano T, Katano S, et al. Utility of the sarcopenia index for assessment of muscle mass and nutritional status in patients with chronic heart failure: comparison with anthropometric parameters. *Geriatr Gerontol Int* **20**: 388-389, 2020.
- Raman M, Middleton RJ, Kalra PA, Green D. Estimating renal function in old people: an in-depth review. *Int Urol Nephrol* **49**: 1979-1988, 2017.
- Yamaguchi Y, Itabashi M, Yumura W, Takei T. Geriatric assessment of estimated glomerular filtration rate: a cross-sectional study. *Clin Exp Nephrol* **24**: 216-224, 2020.
- Légrand H, Werner K, Christensson A, Pihlsgård M, Elmståhl S. Prevalence and determinants of differences in cystatin C and creatinine-based estimated glomerular filtration rate in community-dwelling older adults: a cross-sectional study. *BMC Nephrol* **18**: 350, 2017.
- Shardlow A, McIntyre NJ, Fraser SDS, et al. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: a primary care cohort study. *PLoS Med* **14**: e1002400, 2017.
- Peralta CA, Muntner P, Scherzer R, Judd S, Cushman M, Shlipak MG. A risk score to guide cystatin C testing to detect occult-reduced estimated glomerular filtration rate. *Am J Nephrol* **42**: 141-147, 2015.
- Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. *Am J Med* **118**: 1416, 2005.
- Ye Y, Gai X, Xie H, Jiao L, Zhang S. Impact of thyroid function on serum cystatin C and estimated glomerular filtration rate: a cross-sectional study. *Endocr Pract* **19**: 397-403, 2013.
- Zhai JL, Ge N, Zhen Y, Zhao Q, Liu C. Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure. *Clin Lab* **62**: 203-207, 2016.
- Tsushita H, Tanaka R, Suzuki Y, Sato Y, Itoh H. Effects of dose and type of corticosteroids on the divergence between estimated glomerular filtration rates derived from cystatin C and creatinine. *J Clin Pharm Ther* **45**: 1390-1397, 2020.
- KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl* **2**: 1-138, 2012.
- Horio M, Imai E, Yasuda Y, et al.; Collaborators developing the Japanese equation for estimated GFR. GFR estimation using standardized serum cystatin C in Japan. *Am J Kidney Dis* **61**: 197-203, 2013.
- Gerace L, Aliprantis A, Russell M, et al. Skeletal differences between black and white men and their relevance to body composition estimates. *Am J Hum Biol* **6**: 255-262, 1994.

18. Ortiz O, Russell M, Daley TL, et al. Differences in skeletal muscle and bone mineral mass between black and white females and their relevance to estimates of body composition. *Am J Clin Nutr* **55**: 8-13, 1992.
19. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). *BMC Nephrol* **9**: 9, 2008.
20. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. *Kidney Int* **65**: 1416-1421, 2004.
21. Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight and obesity and elevated serum cystatin C levels in US adults. *Am J Med* **121**: 341-348, 2008.
22. Funamoto M, Shimizu K, Sunagawa Y, et al. Serum cystatin C, a sensitive marker of renal function and cardiovascular disease, decreases after smoking cessation. *Circ Rep* **1**: 623-627, 2019.
23. Yano T, Katano S, Kouzu H, et al. Distinct determinants of muscle wasting in nonobese heart failure patients with and without type 2 diabetes mellitus. *J Diabetes* **13**: 7-18, 2021.
24. Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments. *Front Endocrinol (Lausanne)* **11**: 568, 2020.
25. Wood N, Straw S, Scalabrin M, Roberts LD, Witte KK, Bowen TS. Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence. *ESC Heart Fail* **8**: 3-15, 2021.
26. Luis-Lima S, Higuera Linares T, Henríquez-Gómez L, et al. The error of estimated GFR in type 2 diabetes mellitus. *J Clin Med* **8**: 1543, 2019.
27. Grubb A, Lindström V, Jonsson M, et al. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. *Scand J Clin Lab Invest* **76**: 74-81, 2016.
28. Almén MS, Björk J, Nyman U, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins. *Kidney Int Rep* **4**: 67-79, 2018.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).